Filtering by Tag: DNA
Connecticut-based Tangen has raised $9 million in a series A round to put the company’s TangenDx platform into the clinic in two trials focused on obtaining FDA clearances in diagnosing infectious diseases and commercialize in 2020. TangenDx is a DNA/PCR-based test system that is battery-powered and delivers results in less than one hour.
University of Queensland researchers developed a screening tool to inform clinicians if a patient may have cancer through a simple and inexpensive blood test. However, the procedure does not show where the cancerous cells are located and how serious the patient’s condition is. The test uses gold nanoparticles to detect for cancer DNA and the result is a colour change visible to the naked eye.
Diassess formed a five-year partnership with the Biomedical Advanced Research and Development authority to accelerate its development of its professional flu diagnostic for the clinic as well as to develop an at-home flu diagnostic test. The consumer-focused test will include a smartphone app that will link users to treatment options.
Diassess aims to provide an accurate diagnosis quickly with a nasal swab. The small, battery-powered device would analyze the sample and detect the virus’ genetic information to determine a diagnosis of influenza A or B in under 20 minutes.
Diassess is also developing DNA-based diagnostics for sexually transmitted infections, dengue and Zika fever, and other respiratory illnesses.
A DNA-based blood panel developed by Exact Sciences and the Mayo Clinic accurately detected liver cancer across all stages of the disease and outperformed the most commonly used serum test in a phase 2 clinical validation study.
The assay tracks six methylated DNA markers found in blood plasma to detect hepatocellular carcinoma with 95% overall sensitivity.
Exact Sciences and the Mayo Clinic hope to further optimize the panel and plasma collection conditions prior to a phase 3 study.